NKGN — Nkgen Biotech Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer’S Disease With Adventhealth Orlando As First East Coast Site
Brief: NKGen Biotech Publishes Phase 1 Troculeucel Clinical Trial Results
NKGen jumps on FDA's 'fast track' designation for Alzheimer's drug
Brief: NKGen Biotech Enters Seventh Amendment To Forward Purchase Agreement Dated Sept 22, 2023
Brief: Nkgen Biotech Selected As Preferred Stalking Horse Bidder For Nkmax Co.
Brief: Nkgen Biotech Inc On Nov 5, As Part Of Cost-Reduction Efforts, Conducted A Group Layoff Of 16 Employees.
Brief: Nkgen Biotech Says Co Placed 19 Employees On Furlough
Brief: Nkgen Biotech Size Of Board Temporarily Reduced From Five To Two Directors
Brief: NKGen Biotech Receives Deficiency Letter From Nasdaq
Brief: NkGen Biotech Receives Notification From Nasdaq Related To Delayed Quarterly Report
U.S. STOCKS ON THE MOVE-Palo Alto Networks, Micron, Target
U.S. STOCKS ON THE MOVE-Hims & Hers Health, Dyne Therapeutics, AZZ
Brief: Nkgen Biotech’S Snk01 Nk Cell Therapy Cleared To Start Phase 2 Clinical Trial In Alzheimer’S Disease
U.S. STOCKS ON THE MOVE-Nvidia, Johnson Controls, Paramount Global
NKGen rises on clearance to start mid-stage study on Alzheimer's therapy